All News
Germano et al. Physical exam of temporal arteries predictive of TAB+. Decreased pulse nad thickened artery most useful @rheumnow #ACR22 Abstr#0483 https://t.co/NGvu8pMiaj https://t.co/F0Y9oy0hWy
Richard Conway RichardPAConway ( View Tweet)
Merkel. Vilobelimab in AAV. C5a mab. Phase 2. Given with RTX/CYC. Various steroid regimes (none, reduced, standard). Not powered for non-inferiority but encouraging results. Makes sense, this is the same pathway as avacopan @RheumNow #ACR22 Abstr#0524 https://t.co/HY5i6wqnjI https://t.co/CTXUdP3PZV
Richard Conway RichardPAConway ( View Tweet)
Exciting development in Lupus!
Change in urinary biomarkers (CD163 and MMR) better predictor than proteinuria for lupus nephritis treatment response.
Larger longitudinal studies needed.
Abs#0536
@RheumNow #ACR22
#ACRBest https://t.co/MLSWdl0xUo
Robert B Chao, MD doctorRBC ( View Tweet)
Bandeira et al. When to look for cardiac involvement in IIM. Lung involvement and anti-SRP abs both ORs of >7 main warning signs @rheumnow #ACR22 Abstr#0171 https://t.co/02cKN23Ufq https://t.co/3NioXUwVPM
Richard Conway RichardPAConway ( View Tweet)
Pearl - ‘Three Useful Ophthalmologic Acronyms’ with Dr. John Stone
KP- Keratic Precipitates
PUK- Peripheral Ulcerative Keratitis
IOI- Idiopathic Orbital Inflammation
Add PUK to the Rheum Emergencies. Seen in #RA and #AAV
@RheumNow #ACR22 https://t.co/GUc9boY0WV
Akhil Sood MD AkhilSoodMD ( View Tweet)
Yang et al. Incidence and risk factors for cutaneous lupus becoming SLE. 11.8% transitioned after 20 years. Age<40 (HR 3.25), in first 10 years after skin lupus diagnosis, SCLE>DLE (HR 0.28)/others (HR 0.11) @rheumnow #ACR22 Abstr#0338 https://t.co/IxVS4mOveD https://t.co/3VeQ8WPQtU
Richard Conway RichardPAConway ( View Tweet)
Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quality, emotional disorders, and activity in these patients. Emotional factors more relevant than inflammatory factors on sleep quality. #ACR22 @RheumNow https://t.co/0p5hfNHM91 https://t.co/XrMTmsoMYR
Dr. Rachel Tate uptoTate ( View Tweet)
Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance biggest contributors. Higher in relapsing 122.5 vs 98.9. BMI and neuropsych higher in relapsing. @rheumnow #ACR22 Abstr#0460 https://t.co/dSIt1xEOva https://t.co/2tAkgVEEeA
Richard Conway RichardPAConway ( View Tweet)
Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
Richard Conway RichardPAConway ( View Tweet)
Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm
Dr. Rachel Tate uptoTate ( View Tweet)
Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7
Richard Conway RichardPAConway ( View Tweet)
Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Significantly lower Glucocorticoid toxicity index -29.5 at 12 months -20 at 24 months. Not convinced until I see stronger data! @rheumnow #ACR22 Abstr#0128 https://t.co/20K4dKXE7R https://t.co/X4kJgCqhAE
Richard Conway RichardPAConway ( View Tweet)
Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT
Richard Conway RichardPAConway ( View Tweet)
Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt
TheDaoIndex KDAO2011 ( View Tweet)
Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo.
BMI <25: more AE and SAE
Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD
Robert B Chao, MD doctorRBC ( View Tweet)
Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE
Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK
Robert B Chao, MD doctorRBC ( View Tweet)
Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis.
Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%.
https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7
Aurelie Najm AurelieRheumo ( View Tweet)
MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA.
6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors.
41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group.
Overlapping confidence intervals w/ADA & MTX.
https://t.co/7xtZlDIkVu
Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z
Aurelie Najm AurelieRheumo ( View Tweet)
RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n
@RheumNow #ACR22 #Plenary
Julian Segan JulianSegan ( View Tweet)
GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens.
@RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2
Julian Segan JulianSegan ( View Tweet)